Tau PET in anti-amyloid therapy for Alzheimer's
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Mental health clinical trials.
This study uses brain scans to see how anti-amyloid treatments affect tau protein buildup in people with early Alzheimer's. If you have mild cognitive impairment or mild Alzheimer's, you may be eligible to help understand how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 90 years old.
- You have mild cognitive impairment or mild dementia from Alzheimer's disease.
- You have tested positive for amyloid plaques in your brain (via spinal tap or PET scan).
- You are eligible for anti-amyloid immunotherapy based on other checks by your doctor.
- You can lie still for about 10 minutes during a brain scan.
- You are not pregnant or able to stop breastfeeding for 24 hours if needed.
- You are not very claustrophobic (you can tolerate the scan without sedatives).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This study uses a special brain scan to measure “tau” buildup in people with an inherited form of Alzheimer’s. It may help researchers better understand disease changes and evaluate whether the scan can track them over time.
This trial tests an added brain imaging scan that looks for “tau” protein in people already enrolled in the UAB Alzheimer research studies. Results may help researchers better understand Alzheimer’s disease and improve future diagnosis.
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Hear when a new Dementia, Mild trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.